Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

CTNM

Contineum Therapeutics (CTNM)

Contineum Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CTNM
FechaHoraFuenteTítuloSímboloCompañía
16/12/202415:05Business WireContineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791NASDAQ:CTNMContineum Therapeutics Inc
27/11/202416:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTNMContineum Therapeutics Inc
25/11/202407:05Business WireContineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceNASDAQ:CTNMContineum Therapeutics Inc
18/11/202416:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CTNMContineum Therapeutics Inc
18/11/202407:05Business WireContineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic PainNASDAQ:CTNMContineum Therapeutics Inc
13/11/202415:05Business WireContineum Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:CTNMContineum Therapeutics Inc
06/11/202415:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTNMContineum Therapeutics Inc
06/11/202415:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTNMContineum Therapeutics Inc
06/11/202415:05Business WireContineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CTNMContineum Therapeutics Inc
28/08/202415:05Business WireContineum Therapeutics to Present at Multiple Upcoming Investor ConferencesNASDAQ:CTNMContineum Therapeutics Inc
14/08/202411:19Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CTNMContineum Therapeutics Inc
13/08/202415:05Business WireContineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CTNMContineum Therapeutics Inc
31/07/202415:05Business WireContineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple SclerosisNASDAQ:CTNMContineum Therapeutics Inc
24/06/202415:05Business WireContineum Therapeutics Announces Appointment of Sarah Boyce to Board of DirectorsNASDAQ:CTNMContineum Therapeutics Inc
04/06/202415:05Business WireContineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare ConferenceNASDAQ:CTNMContineum Therapeutics Inc
03/06/202416:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CTNMContineum Therapeutics Inc
03/06/202415:05Business WireContineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate SecretaryNASDAQ:CTNMContineum Therapeutics Inc
20/05/202415:05Business WireContineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsNASDAQ:CTNMContineum Therapeutics Inc
16/05/202415:05Business WireContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CTNMContineum Therapeutics Inc
04/04/202420:02GlobeNewswire Inc.Contineum Therapeutics Announces Pricing of Initial Public OfferingNASDAQ:CTNMContineum Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTNM